Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 – Results from a German cladribine cohort-Reference-Cited by-同舟云学术

Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 – Results from a German cladribine cohort

Published:2024-08 Issue: Volume:88 Page:105704
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Kowarik Markus C.,Ernst Michael,Woitschach Lara,Cepek Lukas,Rau Daniela,Kühnler Benedicta,Schlemilch-Paschen Sylke,Grothe Christoph,Schwab Matthias,Jöstingmeyer Petra,Kleinschnitz Christoph,Pul Refik

Publisher

Elsevier BV

Reference16 articles.

1. Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study;Brownlee;Mult. Scler. Relat. Disord.,2023

2. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study;Comi;Ther. Adv. Neurol. Disord.,2018

3. Treatment patterns prior to and post cladribine in patients with multiple sclerosis;Ellenberger,2022

4. Clinical outcome in people with multiple sclerosis who switched from cladribine to ocrelizumab;Ellenberger,2023

5. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: an ambispective study;Giovannoni;Mult. Scler.,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment continuation with cladribine at 5 years after initiation in people with multiple sclerosis: A case series and literature review;Multiple Sclerosis and Related Disorders;2024-10